THE TAPE
WGS · Health Services · $1.5B

GeneDx Holdings Corp. Class A Common Stock

$51.02▼ −2.58%
Last close
Relative strength
11RS
of 99, against every stock▼ -12 on the month
Falling back
Unconfirmed
+19.3%
six months against the S&P 500
52-week range
−70.1%
from the high
$32.21$170.87
Setup
On no screen
No base, flag or squeeze in place tonight. What is and is not there
No report date on the calendar.
Growth FLATProof PENDING
Quarter to Sep 30, revenue +5% on a year ago
Why it is on no screen

WGS is off the screens on 3 checks.

A base has formed8.6 weeks, from 48.42 to 105.18.
Long enough to count8.6 weeks against 3 needed.
Shallow enough54.0% deep against 35% allowed.
Close to its pivot-51.5% from the pivot; listed down to -20%.
Relative strengthRS 11 against 70 needed.

Measured against the base-and-breakout thresholds. The other screens use their own numbers, so a name can miss here and still be a fair-looking chart.

Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
Support and resistance
Support below
None within the last 120 sessions
Resistance above
$56.81
+11.3% · tested 5× · last 16 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

GeneDx Holdings Corp. Class A Common Stock is not on any of the screens right now. Its relative strength rating is 11, and it sits in Health Services.

Against its industry
UnconfirmedNone of the patterns above holds.
One month against the S&P 500
-17.3%
Three months against the S&P 500
-30.7%
Six months against the S&P 500
+19.3%

Its industry has too few members to make an index of, so it is read against the S&P 500 and can only be turning, caution or unconfirmed.

Peers
Same theme
No themes — common and fine.
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 23.1% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$460.8M
+5.4% year on year
Operating margin
-21.6%
gross 68.7%
Net margin
-24.1%
Free cash flow
$-75.1M
-4.9% of market cap
Price to sales
3.30×
Price to earnings
—
not meaningful on a loss

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Nov 9
Key takeaway
Margins are improving, but the financial turnaround is not yet proven.
Revenue
$123.1M
+7.6% QoQ · +5.4% YoY
Gross margin
69.9%
+1.5 pts QoQ
Net income
−$12.3M
Loss
Free cash flow
−$10.6M
Burning · 9q runway

What the numbers say

  • Revenue +5.4% year over year, +7.6% on the quarter
  • Good: Gross margin 69.9%, +1.5 points on the quarter
  • Weak: Net loss $12M, narrower than $18M last quarter
  • Weak: Burning cash: operating cash flow -$11M, free cash flow -$11M, better than -$29M last quarter · 9 quarters of cash at this burn
  • Net debt $50M · cash $96M
Revenue by quarter
Free cash flow
Net income
shares +3.8% in a year · net debt $50.1M

What is not obvious

  • Weak: Stock compensation $8M added back against negative operating cash flow
  • Weak: Debt $146M, +51% on the quarter; 0.3× trailing revenue

The desk’s own read

Flagged as drifting down since the report

Final read
Growth: FLAT · Economic proof: PENDING
Key question: Can the recovery in margins reach operating profit and cash?
The next test is operating profit: net loss $12M, narrower than $18M last quarter.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 2 of 46 tracked funds at the end of Q3 2026.

Last quarter: 2 added.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
GappedTape · 2026-11-13
-5.9%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-11-11
-16.6%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Moved 5%+ down on earningsTape · 2026-11-11
-16.6% on earnings 2026-11-09
No measurable effect: stocks behave like random ones over the next three sessions (665 cases over 44 nights).
Unusual volumeTape · 2026-11-11
5.7 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.
Closed below its 20- and 50-day on heavy volumeTape · 2026-11-10
below 20d & 50d on 2.2x volume at 65.72
No measurable effect: stocks behave like random ones over the next three sessions (1,780 cases over 60 nights).
GappedTape · 2026-11-10
+5.4%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-11-06
-7.2%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-11-04
+7.1%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Insiders
Bought on the open market
0
Sold on the open market
13
$1,839,245 total

Sold: Stueland Katherine, Feeley Kevin.

Not counted above: 11 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-09-17 Fuchs Thomas · Directoroption exercise1,146
2026-09-16 Stueland Katherine · CHIEF EXECUTIVE OFFICER, Directoroption exercise18,750
2026-09-16 Stueland Katherine · CHIEF EXECUTIVE OFFICER, Directorsell1,648$155,337
2026-09-16 Stueland Katherine · CHIEF EXECUTIVE OFFICER, Directorsell148$14,120
2026-09-16 Stueland Katherine · CHIEF EXECUTIVE OFFICER, Directorsell1,525$147,774
2026-09-16 Stueland Katherine · CHIEF EXECUTIVE OFFICER, Directorsell4,141$406,936
2026-09-16 Stueland Katherine · CHIEF EXECUTIVE OFFICER, Directorsell3,039$300,846
2026-09-16 Feeley Kevin · CHIEF FINANCIAL OFFICERoption exercise7,197

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What analysts expect
Strong buy1
Buy7
Hold0
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray

No completed base to compare this one with yet.

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
GeneDx Holdings Corp. Class A Common Stock (WGS) — The Tape